新型抗凝药物防治静脉血栓栓塞症的研究进展被引量：6

Advances of new anticoagulant drugs in prevention and treatment of venous thromboembolism

导出

摘要静脉血栓栓塞症（VTE）是由多种遗传性和获得性危险因素共同作用的结果，抗凝治疗是预防和治疗VTE的基础。传统抗凝药物如低分子肝素和华法林防治VTE的有效性已被临床实践充分证实，但其缺点也不容忽视。近年来新型抗凝药物如利伐沙班、阿哌沙班和达比加群等在预防和治疗VTE领域进行了大量临床研究，其安全性与有效性均得到证实，为临床医师治疗VTE提供了更多的选择。 Venous thromboembolism （VTE） is a result of a variety of genetic and acquired risk factors. Anticoagulant therapy is the basis for the prevention and treatment of VTE. Effectiveness of traditional anticoagulant drugs such as low molecular weight heparin and warfarin for the prevention and treatment of VTE has been fully confirmed by clinical practice, but their shortcomings also can not be ignored. In recent years, a large amount of clinical researches of new anticoagulant drugs such as rivaroxaban, apixaban and dabigatran have been done in the field of prevention and treatment of VTE. The safety and effectiveness of new anticoagulant drugs also have been confirmed, which provides more choices for clinician.

作者白媛胡晓芸

机构地区山西医科大学第一医院呼吸内科

出处《国际呼吸杂志》 2016年第15期1197-1200,共4页 International Journal of Respiration

关键词新型抗凝药物利伐沙班阿哌沙班达比加群静脉血栓栓塞症 New anticoagulant drugs Rivaroxaban Apixaban Dabigatran Venous thromboembolism

分类号 R543.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献13

1Ieko M, Tarumi T, Takeda M, et al. Synthetic selective inhibitors of coagulation factor X a strongly inhibit thrombin generation without affectinginitial thrombin forming time necessary for platelet activation in hemostasis [J]. J Thromb Haemost, 2004, 2(4) :612-618.
2McCart GM, Kayser SR. Therapeutic equivalency of low- molecular-weight heparins [J]. Ann Pharmaeother, 2002, 36 (6) : 1042-1057.
3Biiller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism [J]. N Engl J Med, 2003,349(18) : 1695-1702.
4Billler HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial[J]. Ann Intern Med, 2004,140(11) :867-873.
5Btiller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with aeutesymptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial [J] Laneet, 2012,379(9811) : 123-129. DOI: 10. 1016/S0140- 6736(11)61505-5.
6EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromhoemholism [J]. N Engl J Med, 2010, 363 (26) : 2499-2510. DOI: 10. 1056/ NEJMoa1007903.
7EINSTEIN-PE Investigators, Bllller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012,366(14) : 1287- 1297. DOI: 10.1056/NEJMoa1113572.
8Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism [J]. N Engl J Med, 2013, 369 ( 9 ): 799-808. DOI: 10. 1056/ NEJMoa1302507.
9Hokusai-VTE Investigators, Btlller HR, Dgeousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thr0mboembolism[J]. N Engl J Med, 2013,369(15): 1406-1415. DOI : 10.1056/NEJMoa1306638.
10Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboemholism [J]. N Engl J Med, 2009, 361 (24): 2342-2352. DOI: 10. 1056/NEJMoa0906598.